Lutsey Pamela L, Misialek Jeffrey R, Whitsel Eric A, Lakshminarayan Kamakshi, Kucharska-Newton Anna M, Windham B Gwen, Sullivan Kevin J, Secora Alex, Grams Morgan E, Farley Joel F
Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis.
Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis.
Mayo Clin Proc. 2025 May 17. doi: 10.1016/j.mayocp.2024.11.030.
To estimate the prevalence of polypharmacy (concomitant use of ≥5 medications), hyperpolypharmacy (≥10 medications), and potentially inappropriate medication (PIM) use among older adults according to dementia and frailty status.
Cross-sectional data (2016-2017) from 3912 participants aged 71 to 94 years (mean ± SD, 79.6±4.8 years; 59.2% female; 24.5% Black race) from the community-based Atherosclerosis Risk in Communities (ARIC) study were used. Dementia and mild cognitive impairment status was based on comprehensive neurocognitive assessment, informant interviews, and adjudication by an expert panel. Participants were classified as frail, prefrail, or robust according to the Fried frailty phenotype definition. Medication containers were brought to the clinic. The PIMs were defined using a modified version of the Beers Criteria.
Polypharmacy, hyperpolypharmacy, and PIM use were prevalent in 67.1%, 18.8%, and 23.9% of participants, respectively, and 7.9% were classified as having dementia and 8.0% as frail. The demographic-adjusted relative risk ratio (95% CI) for participants with dementia vs normal cognition was 1.79 (1.27 to 2.51) for hyperpolypharmacy, and the odds ratio (95% CI) for PIM use was 1.58 (1.21 to 2.06). The relative risk ratios (95% CIs) for hyperpolypharmacy were 8.35 (5.57 to 12.54) for frail and 2.70 (2.14 to 3.41) for prefrail compared with robust.
Polypharmacy, hyperpolypharmacy, and PIM use were common in this community-based sample of adults approximately 80 years old. These patterns of use were even more common among participants with dementia and frailty, who are at elevated risk for adverse outcomes.
根据痴呆和衰弱状态,估计老年人中多重用药(同时使用≥5种药物)、超多重用药(≥10种药物)和潜在不适当用药(PIM)的使用情况。
使用来自社区动脉粥样硬化风险研究(ARIC)的3912名年龄在71至94岁(平均±标准差,79.6±4.8岁;59.2%为女性;24.5%为黑人)参与者的横断面数据(2016 - 2017年)。痴呆和轻度认知障碍状态基于全面的神经认知评估、 informant访谈以及专家小组的判定。根据Fried衰弱表型定义,将参与者分为衰弱、衰弱前期或健壮。药物容器被带到诊所。PIMs使用改良版的Beers标准进行定义。
多重用药、超多重用药和PIM使用在参与者中的患病率分别为67.1%、18.8%和23.9%,7.9%被分类为患有痴呆,8.0%为衰弱。痴呆患者与认知正常参与者相比,超多重用药的人口统计学调整相对风险比(95%置信区间)为1.79(1.27至2.51),PIM使用的比值比(95%置信区间)为1.58(1.21至2.06)。与健壮参与者相比,衰弱者超多重用药的相对风险比(95%置信区间)为8.35(5.57至12.54),衰弱前期者为2.70(2.14至3.41)。
在这个约80岁的社区成人样本中,多重用药、超多重用药和PIM使用很常见。这些用药模式在痴呆和衰弱参与者中更为常见,他们发生不良结局的风险更高。